Research Article

Effect of Micronization on Panax notoginseng: In Vitro Dissolution and In Vivo Bioavailability Evaluations

Table 4

The pharmacokinetic parameters of notoginsenosides following the intragastric administration of 540 mg/kg PNP (n = 6)

NotoginsenosideSampleCmax (ng/mL)Tmax (h)t1/2 (h)MRT (h)AUC0-T (ng·h/mL)AUC0-∞ (ng·h/mL)

R1196.77 ± 8.330.75 ± 0.4361.40 ± 24.4024.39 ± 0.283927.74 ± 168.1915934.90 ± 3756.68
2214.85 ± 46.1618.67 ± 8.6430.85 ± 17.8625.56 ± 1.187988.59 ± 1539.4322347.20 ± 3962.25
3480.12 ± 184.331.31 ± 0.9145.18 ± 19.9423.28 ± 1.6210703.32 ± 195.8826067.99 ± 2653.31
42520.17 ± 699.781.83 ± 1.6810.83 ± 5.8320.42 ± 0.7624392.12 ± 1209.3125608.71 ± 963.71
51325 ± 70.200.15 ± 0.0311.01 ± 0.1310.58 ± 0.195136.15 ± 139.266490.01 ± 2116.24
6585.16 ± 113.860.92 ± 0.3058.53 ± 29.2116.55 ± 1.661832.64 ± 147.304246.85 ± 1457.93

Rg111078.91 ± 221.730.43 ± 0.1522.28 ± 17.7113.64 ± 1.2514876.10 ± 3408.7944835.03 ± 14993.19
21997.5 ± 325.400.96 ± 0.1017.02 ± 3.8119.36 ± 2.0133292.35 ± 6663.8958485.02 ± 38882.91
31577.33 ± 8.171.17 ± 0.4157.43 ± 24.0723.30 ± 2.2326219.02 ± 2116.7973657.82 ± 31451.60
410134.52 ± 4812.271.83 ± 1.687.72 ± 0.8323.04 ± 1.7084696.89 ± 13040.2885766.94 ± 12948.66
510590 ± 230.560.29 ± 0.103.52 ± 0.728.72 ± 0.3823225.07 ± 2017.8223433.90 ± 1935.81
62270.72 ± 670.851.04 ± 0.255.78 ± 1.294.7 ± 0.365396.88 ± 349.555763.17 ± 335.36

Rb119.84 ± 4.9936 ± 13.1442.00 ± 24.0728.69 ± 3.80296.79 ± 85.85770.01 ± 225.94
264.52 ± 27.3322.00 ± 4.9011.17 ± 5.3229.65 ± 0.731756.56 ± 634.272115.94 ± 361.33
376.90 ± 9.9718.00 ± 8.4983.46 ± 52.2122.57 ± 1.002444.21 ± 100.467518.63 ± 3769.97
4741.18 ± 408.392.05 ± 1.7812.37 ± 7.8118.33 ± 1.177212.91 ± 169.4110109.07 ± 4381.42
5331.05 ± 16.350.15 ± 0.0310.85 ± 2.5211.50 ± 0.322031.16 ± 61.082160.99 ± 71.61
6140.71 ± 21.880.79 ± 0.3756.67 ± 31.5418.56 ± 1.291068.46 ± 179.462388.17 ± 841.41

Samples 1 ∼ 6 correspond to Powders 1 ∼ 6., versus Powder 6.